Influence of CRTC1 polymorphisms on body mass index and fat mass in psychiatric patients and the general adult population

JAMA Psychiatry

Volumn 70, Issue 10, 2013, Pages 1011-1019

  Choong, Eva ^a   Quteineh, Lina ^a   Cardinaux, Jean René ^a   Gholam Rezaee, Mehdi ^a   Vandenberghe, Frederik ^a   Dobrinas, Maria ^a   Bondolfi, Guido ^b   Etter, Manuela ^b   Holzer, Laurent ^a   Magistretti, Pierre ^a,c   Von Gunten, Armin ^a   Preisig, Martin ^a   Vollenweider, Peter ^a   Beckmann, Jacques S ^a,d   Pralong, François P ^a   Waeber, Gerard ^a   Kutalik, Zoltan ^d,e   Conus, Philippe ^a   Bochud, Murielle ^f   Eap, Chin B ^a,g  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c EPFL   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^f UNIVERSITY OF LAUSANNE   (Switzerland)

^g UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; BINDING PROTEIN; CLOZAPINE; CREB REGULATED TRANSCRIPTION COACTIVATOR 1 PROTEIN; LITHIUM; OLANZAPINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; SERTINDOLE; UNCLASSIFIED DRUG; VALPROIC ACID; CRTC1 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; ADVERSE OUTCOME; ALLELE; ARTICLE; BODY MASS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG SAFETY; ENERGY BALANCE; FAT MASS; FEMALE; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; MAJOR CLINICAL STUDY; MENTAL PATIENT; MULTICENTER STUDY; PREMENOPAUSE; PRIVATE HOSPITAL; RETROSPECTIVE STUDY; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SWITZERLAND; UNIVERSITY HOSPITAL; WEIGHT GAIN; CASE CONTROL STUDY; COMPLICATION; GENETIC PREDISPOSITION; GENETICS; MALE; MENTAL DISEASE; OBESITY;

ADIPOSITY; ADULT; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MENTAL DISORDERS; OBESITY; POLYMORPHISM, SINGLE NUCLEOTIDE; TRANSCRIPTION FACTORS;

EID: 84885199267     PISSN: 2168622X     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamapsychiatry.2013.187     Document Type: Article

References (58)

1. Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45(1-2):21-28.
2. Heiskanen T, Niskanen L, Lyytikäinen R, Saarinen PI, Hintikka J. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64(5): 575-579.
3. van Winkel R, De HertM,WampersM, et al. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2008;69(3):472-479.
4. Hennekens CH, Hennekens AR, Hollar D, Casey DE. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150(6):1115-1121.
5. Capasso RM, Lineberry TW, Bostwick JM, Decker PA, St Sauver J. Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort: 1950-2005. Schizophr Res. 2008;98(1-3):287-294.
6. De HertM,Mittoux A, He Y, Peuskens J. Metabolic parameters in the short- and long-term treatment of schizophrenia with sertindole or risperidone. Eur Arch Psychiatry Clin Neurosci. 2011;261(4):231-239.
7. van Winkel R, De HertM, Van Eyck D, et al. Prevalence of diabetes and themetabolic syndrome in a sample of patients with bipolar disorder. Bipolar Disord. 2008;10(2):342-348.
8. Garcia-Portilla MP, Saiz PA, Bascaran MT, et al; General Health Status in Bipolar Disorder Collaborative Group. Cardiovascular risk in patients with bipolar disorder. J Affect Disord. 2009;115(3):302-308.
9. Perez-Iglesias R, Vazquez-Barquero JL, Amado JA, et al. Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. J Clin Psychopharmacol. 2008;28(3):289-295.
10. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156(11):1686-1696.
11. ViewegWVR, Levy JR, Fredrickson SK, et al. Psychotropic drug considerations in depressed patients with metabolic disturbances. Am J Med. 2008;121(8):647-655.
12. McIntyre RS, Konarski JZ. Tolerability profiles of atypical antipsychotics in the treatment of bipolar disorder. J Clin Psychiatry. 2005;66(suppl 3):28-36.
13. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality inmiddle-aged men. JAMA. 2002;288(21):2709-2716.
14. Isomaa B, Almgren P, Tuomi T, et al. Cardiovascular morbidity and mortality associated with themetabolic syndrome. Diabetes Care. 2001;24(4):683-689.
15. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-3421.
16. Iversen LB, Strandberg-Larsen K, Prescott E, Schnohr P, Rod NH. Psychosocial risk factors, weight changes and risk of obesity: the Copenhagen City Heart Study. Eur J Epidemiol. 2012;27(2):119-130.
17. Dubois L, Ohm Kyvik K, GirardM, et al. Genetic and environmental contributions to weight, height, and BMI from birth to 19 years of age: an international study of over 12,000 twin pairs. PLoS One. 2012;7(2):e30153.
18. Stunkard AJ, Foch TT, Hrubec Z. A twin study of human obesity. JAMA. 1986;256(1):51-54.
19. Alfredo Martínez J, Enríquez L, Moreno-Aliaga MJ, Martí A. Genetics of obesity [published correction appears in Public Health Nutr. 2009;12(1):136]. Public Health Nutr. 2007;10(10A):1138-1144.
20. Speliotes EK, Willer CJ, Berndt SI, et al MAGIC; Procardis Consortium. Association analyses of 249,796 individuals reveal 18 new loci associated with body mass index. Nat Genet. 2010;42(11):937-948.
21. Kraepelin E. Psychiatrie - Ein Lehrbuch fur Studirende und Aerzte. Vol Funfte, vollstandig umgearbeitete Auflage. Leipzig, Germany: Verlag von Johann Ambrosius Barth; 1896.
22. Ryan MCM, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry. 2003;160(2):284-289.
23. Ryan MCM, Flanagan S, Kinsella U, Keeling F, Thakore JH. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004;74(16):1999-2008.
24. Chagnon YC. Susceptibility genes for the side effect of antipsychotics on body weight and obesity. Curr Drug Targets. 2006;7(12):1681-1695.
25. Correll CU, Malhotra AK. Pharmacogenetics of antipsychotic-induced weight gain. Psychopharmacology (Berl). 2004;174(4):477-489.
26. Malhotra AK, Correll CU, Chowdhury NI, et al. Association between common variants near the melanocortin 4 receptor gene and severe antipsychotic drug-induced weight gain. Arch Gen Psychiatry. 2012;69(9):904-912.
27. Spiegelman BM, Flier JS. Obesity and the regulation of energy balance. Cell. 2001;104(4):531-543.
28. Gao Q, Horvath TL. Neurobiology of feeding and energy expenditure. Annu Rev Neurosci. 2007;30:367-398.
29. Altarejos JY, Goebel N, Conkright MD, et al. The Creb1 coactivator Crtc1 is required for energy balance and fertility. Nat Med. 2008;14(10):1112-1117.
30. Breuillaud L, Halfon O,Magistretti PJ, Pralong FP, Cardinaux JR. Mouse fertility is not dependent on the CREB coactivator Crtc1. Nat Med. 2009;15(9):989-990; author reply 991.
31. Conkright MD, Canettieri G, Screaton R, et al. TORCs: transducers of regulated CREB activity. Mol Cell. 2003;12(2):413-423.
32. Wu Z, Huang X, Feng Y, et al. Transducer of regulated CREB-binding proteins (TORCs) induce PGC-1alpha transcription and mitochondrial biogenesis in muscle cells. Proc Natl Acad Sci U S A. 2006;103(39):14379-14384.
33. Kovács KA, Steullet P, Steinmann M, et al. TORC1 is a calcium- and cAMP-sensitive coincidence detector involved in hippocampal long-term synaptic plasticity. Proc Natl Acad Sci U S A. 2007;104(11):4700-4705.
34. Altarejos JY, Montminy M. CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat Rev Mol Cell Biol. 2011;12(3):141-151.
35. Minokoshi Y, Alquier T, Furukawa N, et al. AMP-kinase regulates food intake by responding to hormonal and nutrient signals in the hypothalamus. Nature. 2004;428(6982):569-574.
36. Kim SF, Huang AS, Snowman AM, Teuscher C, Snyder SH. From the cover: antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase. Proc Natl Acad Sci U S A. 2007;104(9):3456-3459.
37. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601.
38. Choong E, Solida A, Lechaire C, Conus P, Eap CB. Follow-up of themetabolic syndrome induced by atypical antipsychotics: recommendations and pharmacogenetics perspectives [in French]. Rev Med Suisse. 2008;4(171):1994- 1996; 1998-1999.
39. Busner J, Targum SD. The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry (Edgmont). 2007;4(7):28-37.
40. Firmann M, Mayor V, Vidal PM, et al. The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC Cardiovasc Disord. 2008;8:6.
41. Lango Allen H, Estrada K, Lettre G, et al. Hundreds of variants clustered in genomic loci and biological pathways affect human height. Nature. 2010;467(7317):832-838.
42. Heid IM, Jackson AU, Randall JC, et alMAGIC. Meta-analysis identifies 13 new loci associated with waist-hip ratio and reveals sexual dimorphism in the genetic basis of fat distribution. Nat Genet. 2010;42(11):949-960.
43. Lin X, Zhang D. Inference in generalized additivemixed models by using smoothing splines. J R Stat Soc Series B StatMethodol. 1999;61(2):381-400.
44. Wood SN. GAMMs with R. In: Carlin BP, Chatfield C, Tanner M, Zidek J, eds. Generalized Additive Models: An IntroductionWith R. New York, NY: Chapman & Hall/CRC; 2006:319-324.
45. Davison AC, Hinkley DV. Bootstrap Methods and Their Application. Cambridge, England: Cambridge University Press; 1997.
46. Compendium Suisse de Médicaments.Vol 31 e Bâle (Suisse). Basel, Switzerland: Documed SA; 2010.
47. R: a language and environment for statistical computing. http://www.R-project.org. Accessed November 15, 2011.
48. Chiolero A, Prior J, Bovet P, Masson JC, Darioli R. Expectation to improve cardiovascular risk factors control in participants to a health promotion program. J Gen Intern Med. 2008;23(5):615-618.
49. Chiffres et données sur les maladies cardio-vasculaires en Suisse Fondation Suisse de Cardiologie. 1er édition 12.02. www.swissheart.ch. Accessed November 15, 2011.
50. PolyPhen-2 prediction of functional effects of human nsSNPs. http://genetics.bwh.harvard.edu/pph2/. Accessed November 15, 2011.
51. Prentice AM, Jebb SA. Beyond body mass index. Obes Rev. 2001;2(3):141-147.
52. Marques-Vidal P, Bochud M, Mooser V, Paccaud F,Waeber G, Vollenweider P. Obesity markers and estimated 10-year fatal cardiovascular risk in Switzerland. NutrMetab Cardiovasc Dis. 2009;19(7):462-468.
53. Rosenbaum M, Nicolson M, Hirsch J, et al. Effects of gender, body composition, and menopause on plasma concentrations of leptin. J Clin Endocrinol Metab. 1996;81(9):3424-3427.
54. Gebhardt S, Haberhausen M, Heinzel-Gutenbrunner M, et al. Antipsychoticinduced body weight gain: predictors and a systematic categorization of the long-term weight course. J Psychiatr Res. 2009;43(6):620-626.
55. Zhang XY, Tan YL, Zhou DF, et al. Association of clozapine-induced weight gain with a polymorphism in the leptin promoter region in patients with chronic schizophrenia in a Chinese population. J Clin Psychopharmacol. 2007;27(3):246-251.
56. Gregoor JG, van derWeide J, Mulder H, et al. Polymorphisms of the LEP- and LEPR gene and obesity in patients using antipsychotic medication. J Clin Psychopharmacol. 2009;29(1):21-25.
57. Elks CE, Perry JR, Sulem P, et al GIANT Consortium. Thirty new loci for age at menarche identified by ameta-analysis of genome-wide association studies. Nat Genet. 2010;42(12):1077-1085.
58. Song Y, Altarejos J, Goodarzi MO, et al CHARGE Consortium; GIANT Consortium. CRTC3 links catecholamine signalling to energy balance. Nature. 2010;468(7326):933-939.